Inovio Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

• Inovio Pharmaceuticals Inc INO.OQ reported a quarterly adjusted loss of 41 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.31. The mean expectation of five analysts for the quarter was for a loss of 74 cents per share. Wall Street expected results to range from -84 cents to -65 cents per share.

• Revenue was $65.00 thousand​; analysts expected zero.

• Inovio Pharmaceuticals Inc's reported EPS for the quarter was a loss of 51 cents​.

• The company reported a quarterly loss of $19.7 million.

• Inovio Pharmaceuticals Inc shares had risen by 19.0% this quarter and gained 6.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 1.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Inovio Pharmaceuticals Inc is $7.50

This summary was machine generated from LSEG data May 13 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)